Rivoceranib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Rivoceranib
Accession Number
DB14765
Type
Small Molecule
Groups
Investigational
Description

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Structure
Thumb
Synonyms
  • APATINIB
Categories
Not Available
UNII
5S371K6132
CAS number
811803-05-1
Weight
Average: 397.482
Monoisotopic: 397.190260381
Chemical Formula
C24H23N5O
InChI Key
WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
IUPAC Name
SMILES
O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9490441
ChEMBL
CHEMBL3186534

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer of the Ovary / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentNeoplasms2
1Not Yet RecruitingTreatmentMetastatic Cancers / Neoplasms Malignant / Tumors, Solid1
1RecruitingOtherCancer, Advanced1
1RecruitingTreatmentCytochrome P450 Interaction1
1RecruitingTreatmentGastric Adenocarcinoma1
1RecruitingTreatmentMalignancies1
1RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
1RecruitingTreatmentRecurrent and Metastatic Gastric Cancer1
1RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1Unknown StatusTreatmentTumors1
1, 2CompletedTreatmentCancer Patients With Solid Tumors1
1, 2Not Yet RecruitingTreatmentAdvanced Solid Tumors / Excluding T Cell Lymphoma1
1, 2Not Yet RecruitingTreatmentGastric Carcinoma1
1, 2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
1, 2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
1, 2RecruitingTreatmentAdvanced Malignancies / Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma / MSI-H or dMMR Solid Tumors / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentApatinib / Combination Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2RecruitingTreatmentHepatocellular,Carcinoma1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung1
2Active Not RecruitingTreatmentApatinib / Metastasis / Recurrences / Squamous Cell Carcinoma of Esophagus1
2Active Not RecruitingTreatmentCancer of the Ovary1
2Active Not RecruitingTreatmentCancer, Breast3
2Active Not RecruitingTreatmentClinical Benefit Rate / Overall Survival / Progression-free Survival / Therapeutic Agent Toxicity1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach Stage II / Malignant Neoplasm of Stomach Stage IV1
2Active Not RecruitingTreatmentNeoplasms, Esophageal1
2Active Not RecruitingTreatmentStomach Neoplasms1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentEfficacy and Safety1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentNeoplasms, Breast1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
2Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
2Not Yet RecruitingTreatmentAdvanced Pancreatic Cancer1
2Not Yet RecruitingTreatmentAngiogenesis / Cancer treatment / Colorectal Cancers1
2Not Yet RecruitingTreatmentBiliary Carcinoma1
2Not Yet RecruitingTreatmentCancer of the Ovary3
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentCervical Cancers1
2Not Yet RecruitingTreatmentChemotherapy Effect / KRAS Gene Mutation / NSCLC Stage IV / PD-1 Antibody1
2Not Yet RecruitingTreatmentChronic Lung Diseases / Neoplasms / Non-Small-Cell Lung / Respiratory Tract Diseases / Thoracic Neoplasms1
2Not Yet RecruitingTreatmentColorectal Cancers / Neoadjuvant Therapy1
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentGastric Adenocarcinoma1
2Not Yet RecruitingTreatmentGastric Cancer With Positive Exfoliative Cancer Cells1
2Not Yet RecruitingTreatmentGliomas2
2Not Yet RecruitingTreatmentHepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma4
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2Not Yet RecruitingTreatmentLung Cancers2
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach1
2Not Yet RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Not Yet RecruitingTreatmentNK/T-cell Lymphoma1
2Not Yet RecruitingTreatmentNeoplasms, Colorectal1
2Not Yet RecruitingTreatmentNeoplasms, Esophageal1
2Not Yet RecruitingTreatmentPancreatic Cancer Metastatic1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma, Adult, Stage II1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction1
2RecruitingTreatmentAdvanced Biliary Tract Carcinoma / Advanced Primary Liver Cancer1
2RecruitingTreatmentAdvanced Melanoma1
2RecruitingTreatmentAdvanced Triple-Negative Breast Cancer1
2RecruitingTreatmentAngiogenesis Inhibitors´╝îOvarian Neoplasms1
2RecruitingTreatmentApatinib in Maintenance Treatment1
2RecruitingTreatmentApatinib / Esophageal Cancers / Metastatic Esophageal Cancer1
2RecruitingTreatmentApatinib / Lung Cancer Metastatic / Sarcoma, Osteogenic1
2RecruitingTreatmentApatinib / Malignant Ascites1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentBiliary Tract Neoplasms1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentCancer of the Ovary1
2RecruitingTreatmentCancer of the Ovary / Chemotherapeutic Toxicity1
2RecruitingTreatmentCancer, Advanced / Overall Survival / Progression-free Survival / Soft Tissue Sarcoma Adult / Therapeutic Agent Toxicity1
2RecruitingTreatmentCancer, Breast2
2RecruitingTreatmentCarcinoma, Adenoid Cystic1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentGastric Adenocarcinoma1
2RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2RecruitingTreatmentHepatocellular,Carcinoma2
2RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung, Carcinoma1
2RecruitingTreatmentMalignant Melanoma1
2RecruitingTreatmentMalignant Neoplasm of Stomach3
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
2RecruitingTreatmentNasopharyngeal Neoplasms2
2RecruitingTreatmentNeoplasms, Colorectal1
2RecruitingTreatmentNeoplasms, Head and Neck2
2RecruitingTreatmentNeoplasms, Pancreatic1
2RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2RecruitingTreatmentOsteosarcoma, Advanced1
2RecruitingTreatmentRecurrent Cervical Carcinoma / Recurrent, IV-B Cervical cancer1
2RecruitingTreatmentRefractory Cancer1
2RecruitingTreatmentRefractory or Metastatic Esophageal Squamous Cell Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus3
2RecruitingTreatmentThyroid Cancers2
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTwo Different Treatment Methods1
2, 3CompletedTreatmentGastric Carcinoma1
2, 3CompletedTreatmentMetastasis / Sarcoma, Osteogenic1
2, 3Enrolling by InvitationTreatmentCancer, Breast1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma / Pulmonary Metastasis1
2, 3RecruitingScreeningEsophageal Gastric Cardia Type Metaplasia / Esophagus Cancer, Stage III / Esophagus Cancer, Stage IV1
2, 3RecruitingScreeningLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentGastric Carcinoma1
3Active Not RecruitingTreatmentGastric Adenocarcinoma / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentAdvanced or Metastatic Gastric Cancer1
3Not Yet RecruitingTreatmentApatinib / Capecitabine / Digestive System Neoplasms / Molecular Mechanisms of Pharmacological Action / Neoplasms / Neoplasms, Gastrointestinal / Stomach Diseases / Stomach Neoplasms1
3Not Yet RecruitingTreatmentCancer of the Ovary1
3Not Yet RecruitingTreatmentGastric Carcinoma1
3Not Yet RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentLocally Advanced or Metastatic and Unresectable HCC1
3Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentApatinib1
3RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
3RecruitingTreatmentEGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors1
3RecruitingTreatmentIntrahepatic Cholangiocarcinoma / Second-line Treatment1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentMalignant Neoplasm of Stomach1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4CompletedTreatmentCancer of the Ovary / Cancer, Breast / Cervical Cancers / Esophageal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignancies / Malignant Neoplasm of Stomach1
4CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Relapsed /Refractory Diffuse Large B Cell Lymphoma / Relapsed and Refractory1
4Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
4Not Yet RecruitingTreatmentLung Squamous Cell Carcinoma1
4RecruitingOtherStage IV Cancer1
4RecruitingTreatmentNewly Diagnosed Peripheral T-cell Lymphoma1
Not AvailableCompletedTreatmentQuality of Life1
Not AvailableNot Yet RecruitingNot AvailableProgression-free Survival;Progression-free Survival;Disease Control Rate; Safety1
Not AvailableNot Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentMalignant Neoplasm of Stomach1
Not AvailableRecruitingNot AvailableNon-Squamous Non-Small Cell Lung Cancer1
Not AvailableRecruitingTreatmentApatinib / Chemotherapy, Adjuvant / Colorectal Cancers / General Surgery / Outcome, Fatal1
Not AvailableRecruitingTreatmentCervical Cancers1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma2
Not AvailableRecruitingTreatmentPeritoneal Metastases From Gastric Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:25 / Updated on May 21, 2019 12:28